722 844
Statistical analysis:
None.
Obtaining funding:
None.
Administrative, technical, or material support:
None.
Supervision:
Bex.
Other:
None.
Financial disclosures:
Axel Bex certifies that all conflicts of interest,
including specific financial interests and relationships and affiliations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/affiliation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents filed,
received, or pending), are the following: Axel Bex has received company
speaker honoraria from Pfizer; has participated in trials for Pfizer
Europe; has participated in advisory boards for GlaxoSmithKline and
Novartis; is a company consultant for Pfizer and Novartis; and has
received grants/research support from Pfizer. Laurence Albiges has
received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi,
Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding
from Pfizer and Novartis. Bo¨rje Ljungberg has received company speaker
honoraria from GlaxoSmithKline, Roche, Pfizer, and Novartis; has
participated in trials for GlaxoSmithKline, Medivation, Pfizer, and
Janssen R&D; and has been on advisory boards for Pfizer and
GlaxoSmithKline. Karim Bensalah has received grants/research support
from Pfizer and honoraria or consultation fees from Intuitive Surgical.
Milan Hora has received company speaker honoraria from Covidien,
Olympus, Janssen, and Astellas; has participated in trials for Janssen; and
has received grants/research support from Ipsen. Markus A. Kuczyk is a
stock shareholder of Bayer Healthcare, Astellas, Storz, Pfizer, Wyeth, and
Novartis; is a company consultant for Karl Storz, Coloplast, AstraZeneca,
Astellas, Storz, and Hexal; has received company speaker honoraria from
Pfizer, Astellas, Bayer, GlaxoSmithKline, Pierre Fabre, Janssen Cilag, and
Hexal; has participated in trials for the ProtecT Study, Millenium Study
C21004, Millenium Study C21005, Astellas, Ipsen, and Janssen; and has
received grants/research support fromWyeth and Pfizer. Thomas B. Lam
is a company consultant for and has received company speaker
honoraria from Pfizer, GlaxoSmithKline, Astellas, and Ipsen. Axel S.
Merseburger is a company consultant for Ipsen Pharma, Bayer, Astellas,
Janssen Cilag, Novartis, and Pfizer; has received company speaker
honoraria from Ipsen Pharma, Wyeth, Astellas, Novartis, Pfizer, and SEP;
has participated in trials for AstraZeneca, Bayer, Pfizer, TEVA, Novartis,
and Astellas; has received grants/research support fromWyeth; and has
participated in a company-sponsored speakers bureau for TEVA, Janssen,
Pfizer, Astellas, Ferring, and Novartis. Michael Staehler is a company
consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, Astellas, and
Bayer; has received company speaker honoraria from Pfizer, Novartis,
GlaxoSmithKline, Roche, Astellas, Bayer, and Aveo; has participated in
trials for Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer, Aveo, Wilex,
and Immatics; has received fellowships and travel grants from Pfizer,
Novartis, GlaxoSmithKline, Roche, and Bayer; and has received grants/
research support from Pfizer, Novartis, GlaxoSmithKline, Roche, Bayer,
and Aveo. In addition, he took part in the S-TRAC trial as an investigator
and is an author on the S-TRAC publication. Thomas Powles is a company
consultant for Novartis, Pfizer, and GlaxoSmithKline; has received
company speaker honoraria from Novartis, Pfizer, GlaxoSmithKline, and
Genentech; has participated in trials for GlaxoSmithKline, Pfizer, BMS,
Genentech, and Genetech; and has received grants/research support
from GlaxoSmithKline, Pfizer, and Novartis. Saeed Dabestani, Rachel H.
Giles, Fabian Hofmann, Lorenzo Marconi, and Alessandro Volpe have
nothing to disclose.
Funding/Support and role of the sponsor:
None.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2016.11.034.
References
[1]
Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913–24.[2]
Buchler T, Bortlicek Z, Poprach A, et al. Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis. Eur Urol 2016;70: 469–75.[3]
Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high- risk renal-cell carcinoma after nephrectomy. N Engl J Med 2016;375: 2246–54.[4]
Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008–16.[5]
Coleman R, Powles T, Paterson A, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual pa- tient data from randomised trials. Lancet 2015;386:1353–61.[6]
Wheler J, Johnson M, Seidman A. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy. Semin Oncol 2006;33:672–80.[7]
Dowsett M, Forbes JF, Bradley R, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341–52.
[8]
Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015;16:293–300.[9]
Powles T. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. Clin Geni- tourin Cancer 2012;10:67–8.[10]
Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;2012:CD004078.
E U R O P E A N U R O L O G Y 7 1 ( 2 0 1 7 ) 7 1 9 – 7 2 2
722